Valuation: Axsome Therapeutics, Inc.

Market Cap 823.11Cr 731.66Cr 678.15Cr 617Cr 1.16TCr 78TCr 1.18TCr 8.15TCr 3.2TCr 41TCr 3.09TCr 3.02TCr 1,30000Cr P/E 2026 *
-54.4x
P/E 2027 * 38.2x
Enterprise Value 808.35Cr 718.54Cr 665.99Cr 605.94Cr 1.14TCr 77TCr 1.16TCr 8.01TCr 3.14TCr 40TCr 3.03TCr 2.97TCr 1,27600Cr EV / Sales 2026 *
8.49x
EV / Sales 2027 * 5.14x
Free-Float
84.69%
Yield 2026 *
-
Yield 2027 * -
1 day-2.87%
1 week-6.66%
Current month-14.78%
1 month-25.87%
3 months-33.71%
6 months-14.69%
Current year-13.96%
1 week 155.18
Extreme 155.1801
170.8
1 month 155.18
Extreme 155.1801
213.26
Current year 152.28
Extreme 152.28
260.19
1 year 123.5
Extreme 123.5
260.19
3 years 55.02
Extreme 55.02
260.19
5 years 20.63
Extreme 20.63
260.19
10 years 1.94
Extreme 1.94
260.19
Manager TitleAgeSince
Chief Executive Officer 57 12/01/2012
Director of Finance/CFO 51 16/05/2018
Chief Operating Officer 42 01/04/2014
Director TitleAgeSince
Chairman 57 12/01/2012
Director/Board Member 64 01/12/2014
Director/Board Member 58 01/12/2014
Date Insider Type Main position Quantity % Market Cap. Importance
03/09/26 Exercice

Chief Operating Officer

30,000 0.0573%
06/08/26 Exercice

Chief Executive Officer

13,980 0.0272%
01/07/26 Exercice

Chief Executive Officer

1,48,998 0.2895%
Change 5-day change 1-year change 3-year change Capi.($)
-2.87%-6.66%+25.71%+134.85% 823.11Cr
+0.43%+6.59%+53.41%+103.85% 1,12000Cr
+0.90%-2.25%+33.02%+62.23% 62TCr
+0.71%+3.24%+25.81%+93.86% 50TCr
-0.13%+5.98%+32.91%+50.39% 37TCr
+0.52%+0.24%+73.92%+40.15% 36TCr
-0.95%+4.70%+19.51%+43.00% 29TCr
-1.98%+3.73%-0.86%+13.43% 26TCr
-0.35%+4.25%+46.21%+50.76% 23TCr
-0.75%+3.32%+32.53%+97.21% 19TCr
Average -0.45%+2.59%+34.22%+68.97% 39.49TCr
Weighted average by Cap. +0.13%+3.81%+39.15%+71.57%

Financials

2026 *2027 *
Net sales 95Cr 85Cr 78Cr 71Cr 134.74Cr 9.04TCr 136.9Cr 943.36Cr 369.87Cr 4.72TCr 357.5Cr 349.89Cr 15TCr 151.86Cr 134.99Cr 125.12Cr 113.83Cr 214.81Cr 14TCr 218.25Cr 1.5TCr 589.65Cr 7.52TCr 569.93Cr 557.79Cr 24TCr
Net income -15Cr -14Cr -13Cr -11Cr -21Cr -1.44TCr -22Cr -150.49Cr -59Cr -752.59Cr -57Cr -56Cr -2.4TCr 22Cr 20Cr 18Cr 17Cr 31Cr 2.1TCr 32Cr 219.51Cr 86Cr 1.1TCr 83Cr 81Cr 3.5TCr
Net Debt -15Cr -13Cr -12Cr -11Cr -21Cr -1.4TCr -21Cr -146.18Cr -57Cr -731.03Cr -55Cr -54Cr -2.33TCr -42Cr -37Cr -35Cr -32Cr -60Cr -4TCr -61Cr -416.93Cr -163.47Cr -2.09TCr -158Cr -154.64Cr -6.65TCr
Projected Income Statement - Annual - Axsome Therapeutics, Inc.
Logo Axsome Therapeutics, Inc.
Axsome Therapeutics, Inc. is a fully integrated biopharmaceutical company. The Company focused on developing medicines for people impacted by central nervous system (CNS) conditions. Its commercial products include AUVELITY, SUNOSI, and SYMBRAVO. It is also advancing pipeline of novel product candidates in early- to late-stage development addressing a broad range of serious neurological and psychiatric conditions. Its product pipelines include AXS-05, AXS-12, and AXS-14. Its lead product candidate, AXS-05 (dextromethorphan-bupropion), is developed for the treatment of Alzheimer’s disease (AD) agitation and smoking cessation. Its AXS-12 (reboxetine) is a novel, oral, potent, highly selective investigational norepinephrine reuptake inhibitor (NRI) and cortical dopamine modulator being developed for the treatment of narcolepsy. Its AXS-14 (esreboxetine) is a novel, oral, potent, highly selective investigational NRI being developed for the management of fibromyalgia.
Employees
1,346
Date Price Change Volume
16/26/16 $157.14 -2.87% 8,73,152
15/26/15 $161.79 -0.27% 8,02,617
14/26/14 $162.22 +3.77% 8,93,237
13/26/13 $156.32 -5.83% 13,28,730
12/26/12 $166.00 -1.40% 6,63,002
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
MarketScreener Ratings - Axsome Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
157.14USD
Average target price
282.54USD
Spread / Average Target
+79.80%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Axsome Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. AXSM Stock